QVA149
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Introduction: The combination of two bronchodilators with different mechanisms of action to treat patients with chronic…
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological…
OBJECTIVES
QVA149 is a dual bronchodilator, containing a fixed-dose combination of the long-acting β2-agonist indacaterol and…
Introduction Exacerbations are the most frequent cause of hospitalisation and death among patients with COPD. Combinations of…
Introduction
QVA149 is a once-daily dual bronchodilator combining the long-acting β2-agonist indacaterol and long-acting…
Introduction
Current COPD treatment guidelines recommend LABA/ICS for severe COPD patients (pts) with a history of…
Introduction
Patients (pts) with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such…
Introduction
Sustained bronchodilation is thought to contribute to the reduction in exacerbations in patients with COPD. Here…
Introduction QVA149 is a novel inhaled once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2…